Synvichor now available for clinical use in New South Wales and South Australia

OrthoDx

July 15, 2025

Synvichor now available under Authorised Prescriber Pathway

OrthoDx is pleased to confirm that Synvichor is now available for clinical use through TGA-approved Authorised Prescribers, including leading healthcare facilities across New South Wales and South Australia.

Approved by both the Therapeutic Goods Administration (TGA) and relevant Human Research Ethics Committees (HREC), Synvichor enables clinicians to better differentiate inflammation from infection in joint pain.

This advancement offers the potential for substantial cost savings, improved hospital throughput, and earlier intervention for patients.

We look forward to working with health networks to implement Synvichor more broadly across Australia.

Contact details for clinical enquiries – authorisedprescriber@orthodx.com.au